Implanet reports Q4 revenue decline of 20% Y/Y

pepifoto Implanet ( OTC:IMPZY ) reports Q4 revenue declined 20% to €1.64 million. Spine €1.64 million ( 20% Y/Y). Overall, the company reported revenue of €7.45 million in 2023, compared with annual revenue of €8.03 million in 2022. Spine activity recorded revenue of €7.07 million in 2023, compared with €7.93 million in 2022.

The medical equipment distribution activity generated €0.30 million in 2023. The company had a cash position of €0.25 million as of December 31, 2023. According to the company's current cash estimates, this level of cash will allow it to be financed until February 2024. "Finally, the commercial launch of our JAZZ® range in China should start in the coming months, paving the way for a new territory with significant growth potential.

These achievements will enable us to consolidate Implanet's position as an innovative player in spinal surgery, both in France and internationally, said CEO Ludovic Lastennet. The company is slated to release its 2023 annual results on March 5, 2024, after market close. More on Implanet S.A. Historical earnings data for Implanet S.A.

Financial information for Implanet S.A..